
Pacific Biosciences of California, Inc.
PACBNASDAQHealthcareMedical - Devices
最新資料
US$1.36
+US$0.12 · +9.76%
PACB公司概覽
盤中時間採用ET。市場資料可能有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Sell
Trim exposure — unfavorable risk-reward
估值
57
Fair Value
動能
48
Neutral
情緒
43
Mixed
風險韌性
23
High Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
- 產業
- Medical - Devices
- 部門
- Healthcare
- 總部
- US
- 執行長
- Mark Van Oene
- 上市以來
- 2010年10月27日
- 僱員
- 485
市場位置
- 成交量
- 712.36萬
- 1.1× 平均值
- 平均成交量
- 649.56萬
- 日均成交量
- 市值
- 4.19億 USD
- 貝塔
- 2.32
- 市場參考 1
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 12.57億 USD
- 本益比(TTM)
- -3.14×
- 股價淨值比(TTM)
- -12.63×
- 股價營收比(TTM)
- 2.63×
- EV/EBITDA
- -36.75×
- 盈餘收益率
- -97.41%
- 自由現金流收益率
- -20.31%
- 股息率
- 0.00%
獲利能力和效率
- 毛利率
- 35.97%
- 營業利益率
- -102.05%
- 淨利潤率
- -82.49%
- 股東權益報酬率
- -10214.54%
- 資產報酬率
- -69.68%
- 投入資本報酬率
- -76.32%
財務健康
- 負債權益比
- -21.26×
- 流動比率
- 6.89×
- 奧特曼 Z 分數
- -4.71
- 皮奧特羅斯基 F 分數
- 2 共 9 個
財報歷史與展望
- EPS優於預期率
- 40%
- 優於預期4次、低於預期4次、符合預期2次
- 平均EPS意外幅度
- -66.55%
- 10 類似報告
- 最新每股收益結果
- -0.14
- 預估-0.13 · 低於預期9.38%
EPS:實際值與預估值
近期已公布業績
營收:實際值與預估值
近期已公布業績
分析師評級
第三方分析師預期可能變動,並非 GoAI 建議。
分析師目標價
平均目標
US$1.00
下跌空間 25.93%價格歷史記錄不可用
最高:US$1.00平均的:US$1.00最低:US$1.00評級分佈
18項評級近期分析師行動
PACB 訊息
PACB同業公司
持有PACB的ETF
報告持有此股票曝險的交易所交易基金。
ARK Innovation ETFARKK1701.74萬0.26%55.62億 USD0.75%US$86.21+3.53%
ARK Genomic Revolution ETFARKG1493.77萬0.72%——US$49.45+3.80%
Vanguard Morningstar Total Stock Market ETFVTI1334.98萬0.00%2.3兆 USD0.03%US$378.24+0.44%
iShares Russell 2000 ETFIWM890.34萬0.01%816.21億 USD0.19%US$299.96+0.77%
Vanguard Extended Market ETFVXF502.32萬0.01%937億 USD0.05%US$245.53+0.82%
iShares Russell 2000 Growth ETFIWO304.22萬0.02%151.65億 USD0.24%US$387.37+1.24%
iShares Biotechnology ETFIBB266.22萬0.03%107.45億 USD0.44%US$213.56+1.29%
Vanguard Russell 2000 ETFVTWO221.25萬0.01%174億 USD0.06%US$121.25+0.74%
ARK Innovation ETFARKK- 市場價值
- 1701.74萬
- 重量
- 0.26%
- AUM
- 55.62億 USD
- 費用率
- 0.75%
- 價格 / 1日
- US$86.21+3.53%
ARK Genomic Revolution ETFARKG- 市場價值
- 1493.77萬
- 重量
- 0.72%
- AUM
- —
- 費用率
- —
- 價格 / 1日
- US$49.45+3.80%
Vanguard Morningstar Total Stock Market ETFVTI- 市場價值
- 1334.98萬
- 重量
- 0.00%
- AUM
- 2.3兆 USD
- 費用率
- 0.03%
- 價格 / 1日
- US$378.24+0.44%
iShares Russell 2000 ETFIWM- 市場價值
- 890.34萬
- 重量
- 0.01%
- AUM
- 816.21億 USD
- 費用率
- 0.19%
- 價格 / 1日
- US$299.96+0.77%
Vanguard Extended Market ETFVXF- 市場價值
- 502.32萬
- 重量
- 0.01%
- AUM
- 937億 USD
- 費用率
- 0.05%
- 價格 / 1日
- US$245.53+0.82%
iShares Russell 2000 Growth ETFIWO- 市場價值
- 304.22萬
- 重量
- 0.02%
- AUM
- 151.65億 USD
- 費用率
- 0.24%
- 價格 / 1日
- US$387.37+1.24%
iShares Biotechnology ETFIBB- 市場價值
- 266.22萬
- 重量
- 0.03%
- AUM
- 107.45億 USD
- 費用率
- 0.44%
- 價格 / 1日
- US$213.56+1.29%
Vanguard Russell 2000 ETFVTWO- 市場價值
- 221.25萬
- 重量
- 0.01%
- AUM
- 174億 USD
- 費用率
- 0.06%
- 價格 / 1日
- US$121.25+0.74%
繼續GoAI的研究
在 GoAI 中研究PACBresearch.disclaimer











